Intuniv (guanfacine) Drug Information: Overdosage and Contraindications

Pill Identifier Search

May 27, 2012

Intuniv

Adult ADHD (Attention Deficit Hyperactivity Disorder) »

What Is Attention Deficit Hyperactivity Disorder (ADHD)?

Attention deficit hyperactivity disorder (ADHD) is one of the most well-recognized childhood developmental problems. This condition is characterized by inattention, hyperactivity and impulsiveness. It is now known that these symptoms continue into adulthood for about 60% of children with ADHD. That translates into 4% of the US adult population, or 8 million adults. However, few adults are identified or treated for adult ADHD.

ADHD in Adults

Adults with ADHD may have difficulty following directions, remembering information, concentrating, organizing tasks or completing work within time limits. If these difficulties are not managed appropriately, they can cause associated behavioral, emotional, social, vocational and academic problems.

Adult ADHD Stats

ADHD afflicts approximately 3% to 5% of school-age children and an es...

Read the Adult ADHD (Attention Deficit Hyperactivity Disorder) article »

« Previous
1
2
3
4
5
6
7
8
9
10
Next »

Intuniv User Reviews >>

Intuniv

ADHD Symptoms in Children Slideshow Pictures

Take the ADHD Quiz

ADHD in Adults Slideshow Pictures

font size

OVERDOSE

Symptoms

Two cases of accidental overdose of INTUNIV® were reported in clinical trials in pediatric ADHD patients. These reports included adverse reactions of sedation and bradycardia in one patient and somnolence and dizziness in the other patient.

Post-marketing reports of guanfacine overdosage indicate that hypotension, drowsiness, lethargy, and bradycardia have been observed following overdosage. Initial hypertension may develop early and may be followed by hypotension. Similar symptoms have been described in voluntary reports to the American Association of Poison Control Center's National Poison Data System. Miosis of the pupils may be noted on examination. No fatal overdoses of guanfacine have been reported in published literature.

Treatment

Consult a Certified Poison Control Center by calling 1-800-222-1222 for up to date guidance and advice.

Management of INTUNIV® overdose should include monitoring for and the treatment of, initial hypertension, if that occurs, as well as hypotension, bradycardia, lethargy and respiratory depression. Children and adolescents who develop lethargy should be observed for the development of more serious toxicity including coma, bradycardia and hypotension for up to 24 hours, due to the possibility of delayed onset hypotension.

CONTRAINDICATIONS

Patients with a history of hypersensitivity to INTUNIV®, its inactive ingredients [see DESCRIPTION], or other products containing guanfacine (e.g. TENEX®) should not take INTUNIV®.

Last reviewed on RxList: 6/17/2011
This monograph has been modified to include the generic and brand name in many instances.